Synuclein Status Shows Limited Correlation With Brain Microstructure in Early Parkinson's

Molecular Biomarkers and Structural Neurodegeneration in Early Parkinsonism

The clinical diagnosis of Parkinson's disease is increasingly supplemented by molecular biomarkers, most notably the alpha-synuclein seed amplification assay (a technique that detects the presence of misfolded protein aggregates in cerebrospinal fluid or other tissues) [1, 2]. While these assays are becoming essential for ensuring cohort homogeneity in clinical trials, the relationship between a positive molecular signature and the actual pace of neurodegeneration remains complex [3, 4]. Clinicians often face a gap between confirming the presence of synucleinopathy and predicting the structural changes occurring within the brain's microarchitecture. Advanced neuroimaging techniques, such as free-water imaging (a diffusion magnetic resonance imaging method that measures the volume of fluid outside of cells to detect neuroinflammation or tissue atrophy), are being investigated to bridge this gap by tracking the progression of tissue loss [4]. A recent study examines whether molecular status truly reflects the degree of structural damage visible on diffusion magnetic resonance imaging.

Clinical and Imaging Profiles of the PPMI Cohort

The researchers analyzed a total of 462 participants enrolled in the Parkinson's Progression Markers Initiative, a large longitudinal study designed to identify biomarkers of disease progression. Within this cohort, the study utilized the alpha-synuclein seed amplification assay (a molecular test that confirms the pathological aggregation of synuclein proteins). The study population was divided based on these results, identifying 421 individuals with a positive status (SAA+) and 41 individuals with a negative status (SAA-). At the time of the baseline magnetic resonance imaging, clinical evaluations revealed distinct phenotypic differences between the two groups. Specifically, SAA+ individuals exhibited hyposmia (a reduced ability to smell) and had a shorter duration of motor symptoms prior to their baseline imaging compared to those in the SAA- group.

To further characterize the cohort, the study employed the Automated Imaging Differentiation for Parkinsonism (a machine learning tool that uses diffusion imaging signatures to distinguish between Parkinson's disease and atypical parkinsonian syndromes, such as progressive supranuclear palsy or multiple system atrophy). This tool identified Parkinson's disease in 92.4% of the total participants (n = 427), and within this imaging-confirmed subgroup, 91.6% were SAA+. Conversely, the tool classified 7.6% of the participants (n = 35) as having atypical parkinsonism. Despite the different imaging signatures associated with atypical disease, 85.7% of those classified as having atypical parkinsonism were also SAA+, highlighting a complex overlap between molecular protein status and structural imaging classifications in early-stage disease. For clinicians, this overlap underscores that a positive molecular test alone cannot reliably differentiate between classic Parkinson's disease and atypical variants.

Focal Microstructural Divergence in the Superior Cerebellar Peduncle

To identify microstructural differences in patients with early Parkinson's disease, the researchers utilized free-water imaging (a diffusion magnetic resonance imaging technique that quantifies the volume of extracellular water to detect neuroinflammation or neurodegeneration). This analysis specifically compared free-water metrics and free-water corrected fractional anisotropy (a measurement of white matter fiber integrity that accounts for the confounding effects of extracellular fluid) between the SAA+ and SAA- groups. By isolating the free-water component, the study aimed to determine if the presence of alpha-synuclein aggregates correlated with specific patterns of structural brain changes that might serve as markers for disease progression.

The imaging analysis revealed that SAA+ individuals had lower free-water in the superior cerebellar peduncle (a major white matter tract connecting the cerebellum to the midbrain) compared to those in the SAA- group. This focal difference reached statistical significance with a false discovery rate corrected p-value of less than 0.05 (pFDR < 0.05). Despite this localized finding, the researchers observed that positive alpha-synuclein status did not correspond to broader structural changes across the brain. Notably, no significant differences in free-water corrected fractional anisotropy were found between the SAA+ and SAA- groups. This suggests that the presence of synuclein pathology in early disease stages does not necessarily translate to widespread loss of white matter fiber integrity as measured by this diffusion metric.

Implications for Diagnostic Stratification and Disease Monitoring

The findings from this study suggest that while the alpha-synuclein seed amplification assay is a highly sensitive tool for identifying the underlying molecular pathology of Parkinson's disease, it does not necessarily reflect the current state of structural brain damage. The researchers observed that positive alpha-synuclein seed amplification assay status was associated with focal microstructural differences but did not distinguish broader diffusion magnetic resonance imaging changes across free-water and free-water corrected fractional anisotropy metrics. This lack of widespread correlation indicates that the presence of misfolded synuclein aggregates, while a hallmark of the disease, may precede or occur independently of the macro-scale tissue degradation that diffusion imaging is designed to detect in early clinical stages.

For the practicing clinician, these results clarify the role of molecular biomarkers in the diagnostic workup. The study demonstrates that molecular confirmation of synuclein aggregation provides limited stratification of neurodegeneration detected by free-water imaging in early Parkinson's disease. Because the assay status did not align with extensive changes in extracellular fluid volume or white matter fiber integrity, it may not yet serve as a reliable surrogate for measuring the total burden of structural disease or for monitoring short-term progression of tissue loss. Consequently, while a positive assay confirms the synucleinopathy, clinicians should not assume it correlates with a specific degree of neuroanatomical damage at the time of diagnosis, meaning structural imaging and clinical evaluation remain indispensable for staging the disease.

References

1. Rissardo JP, Caprara ALF. Alpha-Synuclein Seed Amplification Assays in Parkinson’s Disease: A Systematic Review and Network Meta-Analysis. Clinics and Practice. 2025. doi:10.3390/clinpract15060107

2. Okuzumi A, Hatano T, Matsumoto G, et al. Propagative α-synuclein seeds as serum biomarkers for synucleinopathies. Nature Medicine. 2023. doi:10.1038/s41591-023-02358-9

3. Tharp E, Martinez-Lemus JD, Schiess MC, Ellmore TM, Suescun J, Shahnawaz M. Role of alpha-synuclein seed amplification assay in Parkinson's disease clinical trials: A case of misdiagnosis.. Clinical parkinsonism & related disorders. 2024. doi:10.1016/j.prdoa.2024.100274

4. Vijiaratnam N, Foltynie T. How should we be using biomarkers in trials of disease modification in Parkinson’s disease?. Brain. 2023. doi:10.1093/brain/awad265